Medical Marijuana, Inc. Subsidiary Kannaway(R) Enters CBG Market in Europe
SAN DIEGO, CA, Dec 10, 2020 (GLOBE NEWSWIRE via COMTEX) —
via NewMediaWire — Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary Kannaway(R) has officially entered the European cannabigerol (CBG) market with the release of its Kannaway(R) Premium CBG made with Organic Hemp Seed Oil.
“Since launching in Europe in 2018, Europe has become one of our best revenue-generating markets as consumers have responded very positively to Kannaway’s wide range of cannabidiol (CBD) products,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “Similar to CBD, CBG is non-psychoactive, meaning it does not cause intoxicating effects. Researchers have conducted and are currently conducting many interesting studies on CBG. We are excited to broaden our product offerings with CBG and are confident the market will be as well.”
Each bottle of Kannaway(R) Premium CBG made with Organic Hemp Seed Oil contains 500 mg of CBG and 200 mg of CBD. The cannabinoids used in the product are derived from organic European hemp and quality certified through the Company’s…